Research

Hormonal

Current postmenopausal hormone therapy is associated with a significantly lower risk of all-cause mortality compared to never use, primarily driven by reduced coronary heart disease mortality.

For postmenopausal women currently using hormone therapy, there is a significant association with reduced all-cause mortality, largely due to lower heart disease death rates. This benefit is most pronounced in women with existing cardiovascular risk factors. However, the benefit diminishes with long-term use (10+ years) due to increased breast cancer mortality. Decisions should be individualized based on risk factors.

GoodSupportsHIGH confidence
After adjustment for confounding variables, current hormone users had a lower risk of death (relative risk, 0.63; 95 percent confidence interval, 0.56 to 0.70) than subjects who had never taken hormones
Francine Grodstein et al. · New England Journal of Medicine · 1997

Why this rating

Large prospective cohort (Nurses' Health Study) with rigorous nested case-control design and adjustment for confounders, though observational.

Source

Postmenopausal Hormone Therapy and Mortality

Francine Grodstein et al. · New England Journal of Medicine · 1997

DOI 10.1056/nejm199706193362501

cohort · n=39734Cited 1,190×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →